Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.

Andrew W Hahn,David D Stenehjem,Benjamin Louis Maughan,Matthew Braithwaite,A Oliver Sartor,Michael B Lilly,Neeraj Agarwal,Roberto Nussenzveig,Elisa Ledet

doi:10.1200/jco.2018.36.15_suppl.5048

Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.

Andrew W Hahn, David D Stenehjem + Show 7 more

https://doi.org/10.1200/jco.2018.36.15_suppl.5048

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology

Publication Date: May 20, 2018

Affiliation: Huntsman Cancer Institute, University of Utah, University of Minnesota, Duluth, Tulane Medical Center, Medical University of South Carolina, Tulane University

#Association Of Genomic Alterations #Abiraterone Acetate #Androgen Axis Inhibitors #Treatment Of Advanced Prostate Cancer #Circulating Tumor DNA #Advanced Prostate Cancer #Genomic Alterations #Initial Responses #Advanced Cancer #Treatment Of Advanced Cancer

Abstract
Full-Text
Similar Papers

Abstract

Listen

5048Background: Two androgen axis inhibitors, enza and AA plus prednisone, are approved for the treatment of advanced prostate cancer (aPC). Although initial responses are common with these agents,...

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with progression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.